#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4860	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2838	496.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1950	1950	C	685	C,A	624,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4310	508.8	0	.	n	.	0	T695C	SNP	695	695	T	1429	1429	C	548	C	493	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4310	508.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	2071	2071	A	664	A,G	622,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4310	508.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2705	2705	C	666	C,T	613,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4310	508.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3331	3331	T	578	T,G	516,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7318	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4310	508.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2779	2779	A	681	A	626	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	708	folP	852	852	100.0	folP.l15.c4.ctg.1	2245	94.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1381	1383	AGC	166;165;166	A;G;C	142;145;141	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1516	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3891	116.7	1	SNP	p	S91F	0	.	.	271	273	TCC	844	846	TCC	134;132;132	T;C;C	119;118;117	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1516	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3891	116.7	1	SNP	p	D95G	0	.	.	283	285	GAC	856	858	GAC	132;131;131	G;A;C	117;118;119	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1516	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3891	116.7	1	SNP	p	D95N	0	.	.	283	285	GAC	856	858	GAC	132;131;131	G;A;C	117;118;119	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	682	mtrR	633	633	99.84	mtrR.l6.c4.ctg.1	1840	110.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	480	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1363	104.0	0	.	n	.	0	C187G	SNP	187	187	C	766	766	G	192	G,A	171,1	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1560	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3780	123.8	1	SNP	p	D86N	0	.	.	256	258	GAC	988	990	GAC	164;160;160	G;A,G;C	144;143,1;147	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1560	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3780	123.8	1	SNP	p	S87W	0	.	.	259	261	AGT	991	993	AGT	161;161;161	A;G;T	142;148;144	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1560	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3780	123.8	1	SNP	p	S87R	0	.	.	259	261	AGT	991	993	AGT	161;161;161	A;G;T	142;148;144	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1560	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3780	123.8	1	SNP	p	S87I	0	.	.	259	261	AGT	991	993	AGT	161;161;161	A;G;T	142;148;144	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1560	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3780	123.8	1	SNP	p	S88P	0	.	.	262	264	TCC	994	996	TCC	161;161;162	T;C;C,A	143;149;146,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1318	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3359	117.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1854	1856	GGC	161;161;161	G;G;C	144;144;142	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1490	1492	GCA	158;158;159	G;C;A	141;144;147	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1493	1495	ATC	159;160;161	A,T;T;C	144,1;146;146	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1505	1507	GTG	161;159;160	G;T;G	147;143;142	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1505	1507	GTG	161;159;160	G;T;G	147;143;142	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2009	2011	ACC	120;120;119	A;C;C	105;102;107	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2063	2065	GCG	120;120;120	G;C,G;G	106;93,3;96	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2063	2065	GCG	120;120;120	G;C,G;G	106;93,3;96	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2186	2188	GGC	139;140;139	G;G,T;C,T	124;122,1;123,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2195	2197	GGC	136;138;138	G,T;G,T;C	119,1;123,1;121	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1108	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2832	116.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2213	2215	CCG	139;139;141	C;C,T;G,C	118;122,1;119,2	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1612	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3502	137.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1756	1758	CTG	159;160;161	C;T,C;G	138;143,1;149	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	874	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2302	113.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	873	873	C	128	C	119	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	128	porB1a	984	176	90.56	porB1a.l15.c17.ctg.1	1479	25.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1328	1330	AAT	16;16;16	A;A;T	16;16;16	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	128	porB1a	984	176	90.56	porB1a.l15.c17.ctg.1	1479	25.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1331	1333	AAT	16;15;15	A;A;T	16;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	128	porB1a	984	176	90.56	porB1a.l15.c17.ctg.1	1479	25.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1343	1345	GTT	15;15;15	G;T;T	15;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	128	porB1a	984	176	90.56	porB1a.l15.c17.ctg.1	1479	25.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1355	1357	GCA	13;13;13	G;C;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	128	porB1a	984	176	90.56	porB1a.l15.c17.ctg.1	1479	25.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1378	1380	GTA	13;13;13	G;T;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	128	porB1a	984	176	90.56	porB1a.l15.c17.ctg.1	1479	25.4	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1387	1387	A	13	A	13	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	G38E	NONSYN	112	114	GGA	596	598	GAA	179;179;178	G;A;A	161;164;164	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	S46G	NONSYN	136	138	AGC	620	622	GGC	179;177;177	G;G;C	161;159;156	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	626	628	GGA	174;175;176	G;G;A	162;160;160	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	T87A	NONSYN	259	261	ACT	743	745	GCT	161;162;162	G;C;T	145;147;143	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	749	751	AGC	161;161;163	A;G;C	144;142;150	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	841	842	CG	179;178	C,G;G	165,1;163	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	844	846	CAG	174;173;173	C;A;G	160;159;161	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	848	850	AAA	174;174;174	A;A,T;A	162;164,1;161	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	911	913	GAA	173;173;174	G;A,T;A	161;158,1;162	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	935	937	GCA	168;168;168	G;C;A	151;151;151	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	1043	1045	CGA	155;158;155	C;G,T,A;A,T	143;141,1,1;138,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1127	1129	ACT	153;153;154	A;C;T	142;140;135	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	1130	1132	CAT	155;154;154	C;A;T	142;141;138	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1136	1138	ATG	154;154;156	A;T;G	145;141;143	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	.	MULTIPLE	766	767	AC	1250	1252	GCA	177;176;176	G;C;A	160;163;163	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	W257R	NONSYN	769	771	TGG	1254	1256	CGG	176;178;178	C;G;G	163;164;165	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	0	.	p	.	0	S258fs	FSHIFT	772	772	A	1257	1257	A	178	A	159	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	1	SNP	p	G120K	1	.	.	358	360	AAG	841	843	CGG	179;178;176	C,G;G;G	165,1;163;163	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	1	SNP	p	A121D	1	.	.	361	363	GAC	844	847	CGC	174;173;174	C;G;C	160;161;162	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	974	porB1b	1047	1047	96.57	porB1b.l15.c30.ctg.1	1776	157.3	1	SNP	p	D121N	0	.	.	361	363	GAC	844	847	CGC	174;173;174	C;G;C	160;161;162	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2888	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5300	162.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2259	2261	AAT	172;173;173	A;A;T	161;162;160	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	428	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1445	88.4	1	SNP	p	V57M	1	.	.	169	171	ATG	770	772	ATG	152;152;151	A;T;G,C	143;140;140,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
